Pharsight

Verity patents expiration

1. Tlando patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304960 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US8778922 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US8865695 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US11433083 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11311555 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11364249 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9949985 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US10716794 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US10226473 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9943527 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11559530 VERITY Oral testosterone undecanoate therapy
Nov, 2037

(13 years from now)

US11464735 VERITY Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE;ORAL

More Information on Dosage

TLANDO family patents

Family Patents

2. Trelstar patents expiration

TRELSTAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5776885 VERITY Sustained and controlled release of water insoluble polypeptides
Jul, 2015

(8 years ago)

US10166181 VERITY Slow release pharmaceutical composition made of microgranules
Jun, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 10, 2013

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Market Authorisation Date: 10 March, 2010

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR

More Information on Dosage

TRELSTAR family patents

Family Patents